Home > Products
Cat. No. Product name CAS No.
DCC2831 Jnj-10311795

Novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase

518062-14-1
DCC2832 Jnj-17029259

Vascular endothelial growth factor receptor-2 (VEGF-2) kinase inhibitor

314267-57-7
DCC2833 Jnj-17148066

Estrogen receptor ESR1 agonist

554431-74-2
DCC2834 Jnj-1930942

Novel Positive Allosteric Modulator of the α7 Nicotinic Acetylcholine Receptor

929562-28-7
DCC2835 Jnj-20788560

Selective delta opioid receptor agonist as a potent and efficacious antihyperalgesic agent

825649-28-3
DCC2836 Jnj-26076713

Novel EthR inhibitor, boosting antituberculous activity of ethionamide

669076-03-3
DCC2837 Jnj-28330835

Selective androgen receptor modulator with minimal prostate hypertrophic activity stimulating sexual behavior in female rats

888072-47-7
DCC2838 Jnj-28583867

Histamine H3 receptor antagonist and serotonin reuptake inhibitor

892407-39-5
DCC2839 Jnj-40068782

Novel potent, selective, and systemically active positive allosteric modulator (PAM) of mGlu2-receptors

950196-50-6
DCC2840 Jnj-40255293

Novel Adenosine A 2A /A 1 Antagonist With Efficacy In Preclinical Models of Parkinson's Disease

1147271-25-7
DCC2841 Jnj-40264796

Negative control for JNJ-40068782

DCC2842 JNJ-40355003 Featured

JNJ-40355003 is a potent and selective atty acid amide hydrolase (FAAH) inhibitor.

1394894-41-7
DCC2843 Jnj-40573663

Negaive control for JNJ-42396302

DCC2844 Jnj-40929837

Novel potent, orally active LTA4H inhibitor

1191044-42-4
DCC2845 Jnj-42396302

Novel inhibitor of PDE10A

1298030-18-8
DCC2846 Jnj-42491293

Novel ago-PAM for the metabotropic glutamate receptor subtype 2 (mGluR2)

1376334-37-0
DCC2847 Jnj-49153390

Novel inhibitor of respiratory syncytial virus (RSV), binding the RSV F glycoprotein and inhibiting membrane fusion

DCC2848 Jnj-53721590

Negative control for JNJ-54119936

DCC2849 Jnj-61432059

Novel TARP γ-8 Selective AMPAR Negative Modulator

2035814-50-5
DCC2850 Jnj-dgat1-a

Selective DGAT1 inhibitor

1092067-85-0
DCC2851 Jnj-dgat2-b

Selective DGAT2 inhibitor

DCC2852 Jns 1-40

Novel cysteine-reactive covalent ligand, selectively targeting C377 of PPP2R1A to impair breast cancer signaling, proliferation, and in vivo tumor growth

DCC2853 Jp1201

Novel SMAC mimetic, sensitizing non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner

DCC2854 Jp4-039

Non-toxic radioprotector GS-nitroxide, improving hematopoiesis in long-term bone marrow cultures (LTBMCs)

1205492-16-5
DCC2855 Jr-220

Non-toxic anti-relapse agent, acamprosate

6933-71-7
DCC2856 Jra-003

Novel selective inhibitor of nuclear translocation of IKKα as the most potent synthetic gibberellin against cancer-derived cell lines, displaying no cytotoxicity in cells derived from noncancerous sources (HEK 293T, HS 578BST, HS 888Lu, HS 895Sk, HUVEC)

DCC2857 Jrc-ii-191

Novel inhibitor of CD4-gp120 binding, blocking the binding of the HIV-1 envelope glycoprotein gp120 to the CD4 receptor

DCC2858 Js399-19

Novel specific inhibitor of Fusarium myosin I; Fungicide

39491-78-6
DCC2859 Jsf-2019

Novel antitubercular agent, inhibiting InhA and FAS-II pathway

DCC2860 Jsf-2513

Novel potent antitubercular agent, inhibiting InhA and FAS-II pathway

DCC2861 Jsi287

Novel ERK inhibitor, alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway

DCC2862 Jte-151

Novel RORγ

1608139-41-8
DCC2863 Jte-607

Cytokine release inhibitor, inhibiting production of IL-1ß, IL-8, IL-6, IL-10 and TNFalpha

188791-71-1
DCC2864 Jtk-853

Novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase

954389-09-4
DCC2865 Jts-653

Novel orally active and selective transient receptor potential vanilloid 1 (TRPV1) antagonist

942614-99-5
DCC2866 Jtt-552

Novel inhibitor of urate transporter 1 (URAT1)

888730-46-9
DCC2867 jtv-506

Novel K(ATP) channel opener

170148-29-5
DCC2868 Jtv-803 Mesylate

Specific inhibitor of factor Xa

247131-79-9
DCC2869 Julolidine Phenoxazone Azide

Novel live-cell peobe of voltage-dependent structural changes of voltage-gated Kv2.1 channels

DCC2870 jwb1-84-1 Trihydrochloride

Novel neuroprotective agent, improving cognitive performances in a transgenic mouse model of AD

491878-69-4
DCC2871 Jwg-115

Novel BET selective inhibitor, targeting BRD4

DCC2872 Jwh-007

Potent cannabinoid (CB) receptor agonist

155471-10-6
DCC2873 Jwu-a021

Novel potent stimulator of glucagon-like peptide-1 (GLP-1) secretion in vitro, also potently stimulating Ca(2+) influx through TRPA1 cation channels, being one of the most potent non-electrophilic TRPA-1 channel agonists

1403610-23-0
DCC2874 Jxl069

Novel potent mitochondrial pyruvate carrier (MPC) inhibitor to treat hair loss

DCC2875 Jy-1-106

Novel BH3 α-helix mimetic, inducing apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak

DCC2876 Jyl-1511

High-affinity partial agonist of the vanilloid receptor

623166-14-3
DCC2877 Jyl-273

Potent TRPV1 agonist

1391826-17-7
DCC2878 Jyl-79

Potent vanilloid receptor (VR1) agonist

289902-64-3
DCC2879 Jy-xhe-053

Selective modulator of GABAA receptors containing the α5 subunit

612526-36-0
DCC2880 Jz-4109

Novel β-Glucocerebrosidase modulator, promoting dimerization of β-glucocerebrosidase and revealing an allosteric binding site, stabilizing wild-type and N370S mutant GCase and increases GCase abundance in patient-derived fibroblast cells

DCC2881 Jz-5029

Novel irreversible β-Glucocerebrosidase modulator

DCC2882 jzad-iv-22

Inhibitor of all three monoamine transporters

1333245-01-4
DCC2883 Jzp-430

Potent, highly selective, and irreversible ABHD6 Inhibitor

1672691-74-5
DCC2884 K00135

Novel potent and selective inhibitor of PIM kinases

869650-21-5
DCC2885 K00518

Novel dual CLK1 and CLK3 inhibitor

DCC2886 K103 Hydrochloride

Novel inhibitor of peptidoglycan synthesis targeting the lipid II precursor

1071544-43-8
DCC2887 K-14585

Novel antagonist for proteinase-activated receptor 2 (PAR2)

880546-17-8
DCC2888 K4610422

Novel norditerpenoid inhibitor of testosterone-5α-reductase

DCC2889 K-8008

Novel inhibitor of the interaction of the N-terminally truncated RXR

2276730-51-7
DCC2890 K-8012

Novel inhibitor of the interaction of the N-terminally truncated RXR

1346513-17-4
DCC2891 Kaempulchraol P

Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression

DCC2892 Kaempulchraol Q

Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression

DCC2893 Kalb001

Novel mGlu4 ligand

DCC2894 Kar425

Novel antimalarial agent, providing protection to malaria-infected mice

1809050-49-4
DCC2895 Kasugamycin

Antibiotic, binding within the mRNA channel of the 30S subunit and inhibiting protein synthesis

6980-18-3
DCC2896 Kb130015

Novel activator of hERG1 potassium channels, blocking native and recombinant hERG1 channels at high voltages, but activating them at low voltages

147030-48-6
DCC2897 Kbh-a42

Novel histone deacetylase inhibitor

798543-50-7
DCC2898 Kbjk557

Novel Plk1 PBD inhibitor, showing a remarkable in vitro anticancer effect by inducing Plk1 delocalization, mitotic arrest, and apoptosis in HeLa cells

DCC2899 Kb-nb165-09

Selective inhibitor of Protein_kinase_D1>protein kinase D (PKD); Inhibitor of cell adhesion and HIV; Inhibitor of herpes simplex virus type 1 replication

172832-10-9
DCC2900 Kbp-088

Novel highly potent dual amylin and calcitonin receptor agonist (DACRA), showing long-lasting improvement of food preference and body weight loss

DCC2901 Kb-r7785

Novel ADAM12 and MMP inhibitor, ameliorating cardiac function in a transverse aortic constriction (TAC) model by inhibiting the proteolytic activation of HB-EGF signaling, exerting its antidiabetic effect by ameliorating insulin sensitivity through the in

168158-16-5
DCC2902 Kc-11404

LTB4 inhibitor for the treatment of b-cell leukemias and lymphomas, potently inhibiting histamine, platelet activating factor,and 5-lipoxygenase

148490-22-6
DCC2903 Kca075

Highly specific transglutaminase 2 (TG2) inhibitor

DCC2904 Kca-1490

Dual PDE3/4 inhibitor

909719-71-7
DCC2905 Kca2 Positive Modulator 2q

Novel potent and Subtype-Selective Positive Modulator of KCa2 Channels

DCC2906 Kcal01

Potent PDZ domain peptide inhibitor that rescues CFTR activity

DCC2907 Kdm4c-in-35

Novel selective KDM4C inhibitor

1841508-48-2
DCC2908 Kdm4-in-i

Novel KDM4 inhibitor

23705-85-3
DCC2909 Kdoam-20

Potent and selective KDM5 inhibitor

DCC2910 Kdoam-21

Potent and selective KDM5 inhibitor

DCC2911 Kemptide Acetate Salt

Phosphate acceptor peptide substrate for cAMP-dependent protein kinase

1629902-50-6
DCC2912 Kf15372

Potent and selective adenosine A1 antagonist with renal protective and diuretic activities

131080-42-7
DCC2913 Kfa1982

Novel and potent factor Xa inhibitor

409358-98-1
DCC2914 Kgchm07

Novel potent peptide dual agonist of opioid/neurokinin 1 receptor

DCC2915 Kh-carb13 Hydrochloride

Novel Pim-1 kinase Inhibitor, dose-dependent decreasing the viability of LS174T and HCT-116 cells

1353572-78-7
DCC2916 Khg21834

Inhibitor of Aβ-induced inflammation

940938-64-7
DCC2917 Khg26693

Novel anti-inflammatory and antioxidant agent, significantly decreasing blood glucose, triglycerides, and cholesterol and increased insulin

1497249-95-2
DCC2918 Ki23057

Novel FGFR2 inhibitor, enhancing the chemosensitivity of drug-resistant gastric cancer cell lines

516523-31-2
DCC2919 Kif18a Inhibitor 23

Novel KIF18A inhibitor, causing significant mitotic arrest in vivo, binding at the interface of KIF18A and tubulin

DCC2920 Ki-ms2-008

Novel Max-binding modulator, attenuating Myc-driven transcription and stabilizing the Max homodimer

DCC2921 kin100

Novel inducer of the ISG54 promoter, causing IRF-3 translocation

299952-11-7
DCC2922 Kir1.1-in-a

Novel potent and selective inhibitor of kir1.1 channels

DCC2923 Kist301072

Novel ROS1 kinase inhibitor

DCC2924 Kist301080

Novel ROS1 kinase inhibitor

DCC2925 Kjm429

Novel TRPV1 antagonist

401907-57-1
DCC2926 Kj-pyr-10

Novel specific inhibitor of MYC

DCC2927 Kkha-761

Potent D3 receptor antagonist with high 5-HT1A receptor affinity

DCC2928 Kl-1156

Novel NF-κB inhibitor and lipopolysaccharide (LPS)-induced nitric oxide production inhibitor

819868-62-7
DCC2929 Kld-12

Self-assembling peptide, forming a hydrogel matrix to support growth of cells in the presence of an ionic solution, enhancing chondrogenic differentiation of bone marrow stromal cells (BMSCs)

800379-47-9
DCC2930 Klebsazolicin

Novel inhibitor of 70S ribosome by obstructing the peptide exit tunnel

2257496-47-0
DCC2931 Klk6-in-32

First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro

DCC2932 Klk6-in-42

First-in-class inhibitor of Kallikrein-related peptidase 6 (KLK6), promoting the differentiation of OPCs into mature oligodendrocytes in vitro

DCC2933 Kl-l9p

Novel antibiotic sensitizer, promoting the rearrangement of the bacterial membrane that enables hydrophobic antibiotics to permeate, strongly sensitizing Gram-negative bacteria to linezolid (Lzd), rifampicin (Rif), or clarithromycin (Clr)

DCC2934 Boc-phe-leu-glup(oph)

0

DCC2935 Km05382

CDK9 inhibitor, inhibiting transcription of GAPDH

882291-64-7
DCC2936 km10340

Selective S1P3 agonist

844635-76-3
DCC2937 Km-5-25

Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe

DCC2938 Km-5-66

Novel inhibitor of the BfrB-Bfd complex, binding BfrB in the P. aeruginosa cytosol, blocking the BfrB-Bfd interaction and inhibiting iron mobilization from BfrB, resulting in cytosolic iron limitation that is manifested in a pyoverdine hyperproduction phe

DCC2939 kmi-1764

Novel BACE1 inhibitor with a non-acidic heterocycle at the P1' position

1469987-42-5
DCC2940 Kmn-010034

Novel Potent Hematopoietic Prostaglandin D2 Synthase (H-PGDS) Inhibitor

DCC2941 Kmn-80

Novel Potent and Selective EP4 Agonist

1628759-75-0
DCC2942 kms80013

Novel inhibitor of amyloid-

930284-65-4
DCC2943 Kms88009

Novel inhibitor of amyloid-β aggregation, ameliorating the neurodegenerative disorder

1089681-42-4
DCC2944 Kmup-3

Novel enhancer of cGMP activity; Aortic smooth muscle relaxant

421556-16-3
DCC2945 Kmup-4

Novel enhancer of cGMP activity; Aortic smooth muscle relaxant

864873-81-4
DCC2946 Kongensin D

Natural anti-TNBC agent, significantly suppressing the triple-negative breast cancer (TNBC) tumor growth without causing side effects

DCC2947 kp1212

Novel non-chain terminating nucleoside analog anti-HIV inhibitor

114522-16-6
DCC2948 Kpt-6604

Novel selective, orally bioavailable, PAK4 allosteric modulator against triple negative breast cancer

DCC2949 Kpu-300

Novel potent antimicrotubule agent, exhibiting potent cytotoxicity against HT-29 cells by strongly binding to tubulin and inducing microtubule depolymn.

1620692-60-5
DCC2950 Kr-12-a4

Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity

DCC2951 Kr-25210

Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus

DCC2952 Kr-31762

Novel KATP channel opener, exerting cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury

DCC2953 Kras(g12c)-in-1

Novel irreversible inhibitor of KRAS(G12C)

DCC2954 Kras4b-in-d14

Novel specific inhibitor of oncogenic KRAS4b signaling, stabilizing the KRAS4b-PDEδ complex and remarkably decreasing tumor size and triggered apoptosis of tumor cells

924249-06-9
DCC2955 Kras4b-pdeδ Stabilizer C19

Novel stabilizer of the KRAS4b-PDEδ complex, decreasing the proliferation of colorectal cancer cells, and increasing apoptosis via decreased activation of oncogenic KRAS4b signaling

1049727-35-6
DCC2956 Krc-108

Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met

1146944-35-5
DCC2957 Krc-327

Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity.

1350612-75-7
DCC2958 Krm-ii-08

Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c

DCC2959 Krn4884

Potassium channel opener

152802-84-1
DCC2960 Krn-8602 Hydrochloride

Topo II inhibitor, exhibiting cytotoxic effects against tumour cells

131722-57-1
DCC2961 Krp-109

Novel neutrophil elastase (NE) inhibitor, decreasing expression of TGF-ß Signal Related Genes

1275996-50-3
DCC2962 Krp-199

Highly potent and selective antagonist for the AMPA receptors, exhibiting good neuroprotective effects in vivo

221164-28-9
DCC2963 Krp-204

Novel highly selective β3-adrenoceptor agonist being developed for the treatment of diabetes and obesity

220475-76-3
DCC2964 Ks-133

Novel Potent and Selective VIPR2 Antagonist, Counteracting Cognitive Decline in a Mouse Model of Psychiatric Disorders

DCC2965 Ksc-392-150

Novel inhibitor of the permeability transition pore (PTP)

DCC2966 kscm-1

Selective ligand of the sigma-1 receptor

1415247-17-4
DCC2967 Kscm-11

Ligand of the sigma receptor

1415247-16-3
DCC2968 kscm-5

Ligand of the sigma receptor

1415247-18-5
DCC2969 Ksk120

Novel inhibitor of transcriptional activity in Chlamydia trachomatis

1638100-63-6
DCC2970 Ksl-128114

Novel, highly potent, and metabolically stable peptide inhibitor of syntenin, Inhibiting Glioblastoma

DCC2971 Kspa-1

Novel modulator of kinesin spindle protein (KSP)/Eg5, activating KSP-catalyzed ATP hydrolysis in the absence of microtubules yet inhibiting microtubule-stimulated ATP hydrolysis by KSP

264207-32-1
DCC2972 Kt-182

Potent and selective inhibitor of ABHD6

1402612-62-7
DCC2973 Kt2-962

TXA2/prostaglandin endoperoxide receptor antagonist

129648-96-0
DCC2974 Kta-439

Thyroid hormone receptor β (TRβ) selective agonist

575503-70-7
DCC2975 Ku-2285

Hypoxic cell radiosensitizer

121077-11-0
DCC2976 Kufal194

Novel selective DYRK1A inhibitor

DCC2977 Kunb31

Novel potent and selective inhibitor of Hsp90β

2220263-80-7
DCC2978 Kurasoin B

Novel protein farnesyltransferase inhibitor

193696-42-3
DCC2979 kv1.5-in-iiii

Potent Kv1.5 inhibitor

1469902-72-4
DCC2980 Kv2.1/syntaxin-in-cpd5

Novel neuroprotectant, inhibiting Kv2.1-syntaxin molecular interaction

DCC2981 Kva-d-88

Novel Preferable Phosphodiesterase 4B (PDE4B) Inhibitor, Decreasing Cocaine-Mediated Reward Properties in Vivo

2410550-31-9
DCC2982 Ky1022

Ras destabilizer, targeting the Wnt/ß-catenin pathway and inhibiting development of metastatic colorectal cancer

1029721-36-5
DCC2983 Kya1797

Novel inhibitor of the Wnt/ß-catenin pathway, binding directly to the regulators of G-protein signaling domain of axin, initiating ß-catenin and Ras degradation through enhancement of the ß-catenin destruction complex activating GSK3ß, effectively suppres

851304-36-4
DCC2984 Kys05047

Selective T-type Ca(2+) channel blocker with anti-proliferative effects against various cancer cells

839672-57-0
DCC2985 L-161240

Potent inhibitor of LpxC and lipid A biosynthesis

183298-68-2
DCC2986 L-162782

Nonpeptide agonist of angiotensin AT1 receptor

169281-92-9
DCC2987 L17er4

Novel cell-permeable attenuated cationic amphiphilic lytic (ACAL) peptide, efficiently bring immunoglobulin G (IgG) and other functional proteins into cells

DCC2988 L2-4048

Novel Migration Inhibitory Factor (MIF) inhibitor, binding at the allosteric and tautomerase sites, blocking MIF's tautomerase CD74 receptor binding, and pro-inflammatory activities

DCC2989 L458-bpyne

Novel γ-secretase modulator photoaffinity probe, identifying distinct allosteric binding sites on presenilin that can be exploited to reduce levels of pathogenic Aβ species

1374647-07-0
DCC2990 L465046 (α-synuclein Amyloid Aggregation Inhibitor)

Novel inhibitor of α-synuclein amyloid aggregation for the treatment of Parkinson's disease

675171-18-3
DCC2991 L524-0366

Novel inhibitor of the TWEAK-Fn14 signaling cascade

951612-19-4
DCC2992 L61h46

Novel potent inhibitor of human pancreatic cancer cells

DCC2993 L-651392

Potent leukotriene inhibitor

93211-49-5
DCC2994 L-658758

Blocker of the activity of human neutrophil elastase (NE), human proteinase-3, human macrophage metalloelastase, mouse macrophage metalloelastase and Pseudomonas aeruginosa elastase

116507-04-1
DCC2995 L-663581

Novel partial agonist of the benzodiazepine receptor

122384-14-9
DCC2996 L-680833

Potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase (PMNL-E)

127063-08-5
DCC2997 L-682679

HIV protease inhibitor

126409-24-3
DCC2998 L-687306

Novel partial agonist of muscarinic M1 receptors

139346-23-9
DCC2999 L-696229

HIV-1 non-nucleoside reverse transcriptase inhibitor

135525-71-2
DCC3000 L-708906

Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1)

251963-74-3
DCC3001 L-731988

Inhibitor of Strand Transfer, Preventing Integration and Inhibiting HIV-1 Replication in Cells

251922-77-7
DCC3002 L-735821

Inhibitor of the KCNQ1 channel

170228-29-2
DCC3003 L-739758

Potent glycoprotein IIb/IIIa inhibitor

168157-33-3
DCC3004 L-744832

Ras farnesyltransferase inhibitor, inhibiting in p70(s6k) phosphorylation in mammary tumors, inducing tumor regression in transgenic mice by mediating alterations in both cell cycle control and apoptosis

1177806-11-9
DCC3005 L-749329

Dual ET(A)/ET(B) endothelin receptor antagonist

159590-37-1
DCC3006 L-768673

Class III antiarrhythmic agent, selectively blocking the slowly activating cardiac delayed rectifier potassium current Iks

177954-68-6
DCC3007 L-770644

Potent and selective agonist of the human beta3 adrenergic receptor

173901-95-6
DCC3008 L-778123 Featured

L-778123 is a dual FPTase and GGPTase-I inhibitor, with IC50s of 2 nM and 98 nM respectively.

183499-57-2
DCC3009 L-841411

Novel HIV-1 integrase strand transfer inhibitor (INSTI), stabilizing an integrase-single blunt-ended DNA complex

DCC3010 L-858051

Chemically-modified forskolin with greater stability and water solubility than the parent compound

115116-37-5
DCC3011 L-870812

Novel inhibitor of HIV-1 and SIV integrase

410545-90-3
DCC3012 L-94901

The first organ-selective thyromimetic, lowering plasma low density lipoprotein (LDL) cholesterol and raising plasma high density lipoprotein (HDL) cholesterol levels

DCC3013 L-97-1

Adenosine A1 receptor antagonist, reducing allergic responses to house dust mite in an allergic rabbit model of asthma, improving survival and protecting the kidney in a rat model of cecal ligation and puncture induced sepsis, also improving survival and

770703-20-3
DCC3014 Lamellarin D

Top1mt inhibitor, targeting mitochondrial DNA

97614-65-8
DCC3015 la-mem

Glutamate receptor antagonist and radical scavenging agent

1552275-56-5
DCC3016 Lanopepden Mesylate

Novel Peptide Deformylase Inhibitor against Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus

1441390-17-5
DCC3017 laquinimod Sodium

Novel Modulator of autoimmune demyelination

248282-07-7
DCC3018 Largazole

Potent inhibitor of histone deacetylase

1009815-87-5
DCC3019 Las191859

Novel, potent and selective CRTh2 antagonist

DCC3020 Lasiojasmonate A

Natural fungal phytotoxin, activating the plant jasmonic acid pathway

DCC3021 Laspartomycin C

Lipopeptide antibiotic with activity against a range of Gram-positive bacteria including drug-resistant pathogens

DCC3022 Lassbio-1135

Novel dual TRPV1 antagonist and TNF-alpha production inhibitor

852453-71-5
DCC3023 Lassbio-1359

Novel adenosine receptor agonist, inducing relaxation of corpus cavernosum; Novel selective phosphodiesterase-​4 (PDE4) inhibitor associated with anti-​TNF-​α properties

1396397-19-5
DCC3024 Lassbio-1366

Novel Adenosine A2a Receptor Agonist, Attenuating the Progression of Monocrotaline-induced Pulmonary Hypertension

1396397-03-7
DCC3025 Lassbio-1524

Novel IKK-β inhibitor, reducing the secretion of TNF-α, IL-1β, IL-6, IL-12, IFN-γ and increased secretion of IL-10, protecting gastrointestinal homeostasis

DCC3026 Lassbio-1829 Hydrochloride

Novel orally active IKK2 inhibitor

1807810-16-7
DCC3027 Lassbio-1911

Novel Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitor

DCC3028 Latonduine A

Natural F508del-CFTR corrector, inhibiting both PARP-3 and -16, regulating the activity of the unfolded protein response activator inositol-requiring enzyme (IRE-1) via modulation of the level of its ribosylation by PARP-16

DCC3029 Latonduine B

Natural F508del-CFTR trafficking corrector, targeting poly(ADP-ribose) polymerase (PARP)

DCC3030 Latrunculin A

Disruptor of microfilament-mediated processes

76343-93-6
<Prev1...180181182183184...215Next>